G5779
Gly-Pro-Arg-Pro amide
≥97% (HPLC)
Synonym(s):
GPRP amide, Glycine-Proline-Arginine-Proline amide, Glycyl-L-prolyl-L-arginyl-L-prolinamide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C18H32N8O4
CAS Number:
Molecular Weight:
424.50
MDL number:
UNSPSC Code:
12352209
PubChem Substance ID:
NACRES:
NA.32
Recommended Products
Quality Level
Assay
≥97% (HPLC)
storage temp.
−20°C
SMILES string
NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2CCC[C@H]2C(N)=O
InChI
1S/C18H32N8O4/c19-10-14(27)25-8-3-6-13(25)16(29)24-11(4-1-7-23-18(21)22)17(30)26-9-2-5-12(26)15(20)28/h11-13H,1-10,19H2,(H2,20,28)(H,24,29)(H4,21,22,23)/t11-,12-,13-/m0/s1
InChI key
SCCTZYGEMPQRCV-AVGNSLFASA-N
Gene Information
human ... FN1(2335)
mouse ... FN1(14268)
rat ... FN1(25661)
Amino Acid Sequence
Gly-Pro-Arg-Pro-NH2
General description
Gly-Pro-Arg-Pro is a peptide that mimics the N-terminal Gly-Pro-Arg region in the a chain of fibrin protein.
Application
Gly-Pro-Arg-Pro amide has been used-
- as a constituent of buffer during fluid-phase and bound thrombin inhibition assays, to determine the activity of thrombin
- for blocking fibrin polymerization and preventing fibrin clot formation in presence of α-thrombin, in blood obtained from mice
- during preparation of human soluble fibrin, to block the polymerization of soluble fibrin
Biochem/physiol Actions
Gly-Pro-Arg-Pro peptide suppresses the early steps of fibrin polymerization. The amide derivative of this peptide prevents the degradation of fibrinogen and fragment D by plasmin, even in the presence of EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid).
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
P Klement et al.
Journal of thrombosis and haemostasis : JTH, 1(3), 587-594 (2003-07-23)
Although hirudin is better than heparin at preventing recurrent ischemia in patients with unstable angina, hirudin produces more bleeding. The purpose of this study was to use a rabbit arterial thrombosis prevention and ear bleeding model to determine whether for
P C Liaw et al.
The Journal of biological chemistry, 276(24), 20959-20965 (2001-04-11)
Although fibrin-bound thrombin is resistant to inactivation by heparin.antithrombin and heparin.heparin cofactor II complexes, indirect studies in plasma systems suggest that the dermatan sulfate.heparin cofactor II complex can inhibit fibrin-bound thrombin. Herein we demonstrate that fibrin monomer produces a 240-fold
Chuen Wen Tan et al.
Methods in molecular biology (Clifton, N.J.), 1967, 305-321 (2019-05-10)
Flow cytometry assessment of platelets using the combination of GSAO [4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid], a dithiol-reactive probe, and P-selectin, a platelet activation marker, is a novel and powerful assay in the identification and quantification of the procoagulant subpopulation of platelets that has
K Kawasaki et al.
Chemical & pharmaceutical bulletin, 40(12), 3253-3260 (1992-12-01)
N-Terminal tetrapeptide analogs of fibrin alpha-chain were synthesized by the solution method using a new active ester, the ester of the oxime of p-nitroacetophenone, and by the solid-phase method. Their inhibitory effects on fibrinogen/thrombin clotting were examined. Of the synthetic
Christine S M Lee et al.
Methods in molecular biology (Clifton, N.J.), 2663, 441-461 (2023-05-19)
Heparin-induced thrombocytopenia (HIT) is a well-characterized, iatrogenic complication of heparin anticoagulation with significant morbidity. In contrast, vaccine-induced immune thrombotic thrombocytopenia (VITT) is a recently recognized severe prothrombotic complication of adenoviral vaccines, including the ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and Ad26.COV2.S (Janssen
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service